Novartis Access® offers a portfolio of on- and off-patent medicines addressing key noncommunicable diseases (NCDs): cardiovascular diseases, type 2 diabetes, respiratory illnesses and breast cancer.
The Novartis Access portfolio is offered as a basket to governments, NGOs and other institutional customers in lower-income countries. Building on key learnings from our activities on the ground, we have evolved toward a more flexible approach to better respond to country requirements and local disease burdens. In some countries, we continue to offer the full portfolio at an average price of USD 1 per treatment per patient, per month, but in others only a sub-set or single molecules at variable prices per molecule. Depending on public subsidy levels, patients in participating countries may either receive Novartis Access medicines free of charge or purchase them at a low price to manage their chronic condition long-term. For those who need to purchase their treatments, we are working with our partners to minimize markups.
The products included in the Novartis Access portfolio have been selected based on three criteria: significant health needs, medical relevance, and lack of local access programs. The portfolio aims to offer various treatment options, including well-proven and standard first-line treatments as well as some of the latest treatment choices. Most of the medicines in the portfolio are either on or belong to a class on the World Health Organization’s Model List of Essential Medicines and are among the most commonly prescribed medicines. The treatments in the portfolio offer the same quality and supply security as medicines sold in developed countries. In addition, they have all been qualified for use in tropical climates.
Beyond the portfolio, Novartis Access offers capacity building activities to support healthcare systems in preventing, diagnosing and treating NCDs.
Novartis Access is being rolled out in sub-Saharan Africa, Southeast Asia, Central America and Commonwealth of Independent States (CIS). Since launch, the program has reached 5.4 million patients in 11 countries.